Biosplice Therapeutics, Inc.
Clinical Trials
22
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 496
- Registration Number
- NCT05603754
- Locations
- 🇺🇸
Tucson Orthopaedic Institute, Tucson, Arizona, United States
🇺🇸Core Healthcare Research, Cerritos, California, United States
🇺🇸BioSolutions Clinical Research Center, La Mesa, California, United States
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
- Conditions
- Castration-resistant Prostate CancerNon-small Cell Lung CancerColorectal Cancer
- Interventions
- Drug: FOLFIRI Protocol
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05084859
- Locations
- 🇺🇸
The University of Arizona Cancer Center (UACC) - North Campus, Tucson, Arizona, United States
🇺🇸University of Colorado, Anschutz, Aurora, Colorado, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the Knee
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT04931667
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
- Conditions
- Drug-Drug Interaction
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04598542
- Locations
- 🇺🇸
Research Site, Miami, Florida, United States
A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 276
- Registration Number
- NCT04520607
- Locations
- 🇺🇸
Research Site, Charlottesville, Virginia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next